Crossmark

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Crossref DOI link: https://doi.org/10.1186/s12885-018-5183-y

Published Online: 2018-12-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ettrich, Thomas J. https://orcid.org/0000-0002-7654-2442
Berger, Andreas W.

Perkhofer, Lukas

Daum, Severin

König, Alexander

Dickhut, Andreas

Wittel, Uwe

Wille, Kai

Geissler, Michael

Algül, Hana

Gallmeier, Eike

Atzpodien, Jens

Kornmann, Marko

Muche, Rainer

Prasnikar, Nicole

Tannapfel, Andrea

Reinacher-Schick, Anke

Uhl, Waldemar

Seufferlein, Thomas
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 11 August 2017

Accepted: 4 December 2018

First Online: 29 December 2018

Ethics approval and consent to participate

: The ethics committee of Ulm University approved the NEONAX-trial as leading ethics committee for all German sites. In addition, local ethics committees approved the participating sites. The trial is registered with(NCT02047513) and the European Clinical Trials Database (2013–005559-34). All patients signed informed consent according to GCP.

: Not applicable.

: Gemcitabine and nab-Paclitaxel were provided by Celgene. Otherwise, the authors declare no conflicts of interest. The trial was sponsored by Celgene.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below